FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Plus Therapeutics, Inc. Enters Commercial Manufacturing Supply Agreement with RadioMedix”
Plus Therapeutics, Inc. (NASDAQ: PSTV) climbed 18% in premarket trading after the company announced that it had entered into an agreement with RadioMedix, Inc. for the commercial production of the Company’s radiopharmaceuticals.
RadioMedix will now produce the cGMP drug product meeting all applicable requirements of the U.S. Food and Drug Administration and similar global regulatory entities, while this strategic partnership further secures the commercial supply chain for RNL and extends to future products under the RNL platform.
Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics with nanoliposome-encapsulated radionuclides for rare and difficult-to-treat cancers. Central to the Company’s drug development is a unique nanotechnology platform designed to formulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers.
For more information, please visit: Plus Therapeutics, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.